Chemically stable inhibitors of 14-3-3 protein-protein interactions derived from BV02.
14-3-3 Proteins
/ antagonists & inhibitors
Antineoplastic Agents
/ chemical synthesis
Benzamides
/ chemical synthesis
Cell Proliferation
/ drug effects
Dose-Response Relationship, Drug
Drug Screening Assays, Antitumor
HeLa Cells
Humans
K562 Cells
Molecular Structure
Protein Binding
/ drug effects
Pyrazoles
/ chemical synthesis
Structure-Activity Relationship
14-3-3
4-aminoantipyrine
c-Abl
leukaemia
protein–protein interaction
Journal
Journal of enzyme inhibition and medicinal chemistry
ISSN: 1475-6374
Titre abrégé: J Enzyme Inhib Med Chem
Pays: England
ID NLM: 101150203
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
entrez:
8
2
2019
pubmed:
8
2
2019
medline:
23
2
2019
Statut:
ppublish
Résumé
14-3-3 are regulatory proteins that through protein-protein interactions (PPI) with numerous binding partners could be involved in several human diseases, including cancer, neurodegenerative disorders, and pathogens infections. Following our research interest in the development of 14-3-3 PPI inhibitors, here we exploited the privileged 4-aminoantipyrine scaffold in the design and synthesis of some derivatives endowed with antiproliferative activity against K-562 cells, and capable of binding to recombinant 14-3-3σ as evidenced by NMR spectroscopy. The binding mode was further explored by molecular modelling, while coupling confocal microscopy with intensitometric analysis showed that compound 1 was able to promote the nuclear translocation of c-Abl at low micromolar concentrations. Overall, 1 is chemically stable compared to parent 14-3-3 PPI inhibitors, and thus emerged as a confirmed hit for further development.
Identifiants
pubmed: 30727786
doi: 10.1080/14756366.2019.1574779
pmc: PMC8853708
doi:
Substances chimiques
14-3-3 Proteins
0
Antineoplastic Agents
0
BV02 compound
0
Benzamides
0
Pyrazoles
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
657-664Références
ChemMedChem. 2014 May;9(5):973-83
pubmed: 24715717
Annu Rev Biophys Biomol Struct. 2005;34:245-66
pubmed: 15869390
J Mol Biol. 1997 Apr 4;267(3):727-48
pubmed: 9126849
Drug Discov Today Technol. 2013 Dec;10(4):e541-7
pubmed: 24451646
Bioorg Med Chem Lett. 2010 Oct 15;20(20):6133-7
pubmed: 20832303
Proteins. 2003 Sep 1;52(4):609-23
pubmed: 12910460
J Chem Inf Model. 2015 Dec 28;55(12):2611-22
pubmed: 26551337
ACS Chem Biol. 2015 Sep 18;10(9):1964-9
pubmed: 26121309
J Med Chem. 2018 May 10;61(9):3755-3778
pubmed: 28968506
J Biol Chem. 2005 May 13;280(19):18891-8
pubmed: 15731107
Curr Med Chem. 2018;25(1):5-21
pubmed: 28462702
Plant Mol Biol. 2002 Dec;50(6):993-1010
pubmed: 12516867
Molecules. 2018 Jun 08;23(6):
pubmed: 29890630
Int J Cancer. 2008 Jan 15;122(2):289-97
pubmed: 17893873
Bioorg Med Chem Lett. 2011 Nov 15;21(22):6867-71
pubmed: 21962576
Methods Enzymol. 2003;362:417-34
pubmed: 12968380
Proc Natl Acad Sci U S A. 1988 Oct;85(19):7084-8
pubmed: 2902623
J Pharmacol Exp Ther. 2011 Mar;336(3):596-604
pubmed: 21041536
Bioorg Med Chem Lett. 2016 Feb 1;26(3):894-898
pubmed: 26774582